GNLX

Genelux is a late clinical-stage oncolytic-virus company with no approved products and, by its own MD&A, 'have not generated any revenue from product sales.' The $8.00K FY2025 'revenue' is a rounding artifact, which makes the 16,746x P/S and the -415,175% operating margin meaningless — this equity trades entirely on the clinical prospects of lead candidate Olvi-Vec, not on financials. That is the definition of an unknowable, binary outcome: valuation cannot anchor to fundamentals when there are none.

The balance sheet is the acute problem. FY2025 ended with just $5.33M cash against a -$25.3M operating cash burn and a -$32.1M net loss — roughly a month or two of runway on year-end cash alone. Total assets fell 45.2% to $19.0M, current assets fell 52.0%, stockholders' equity dropped 56.1% to $11.5M, and the accumulated deficit swelled to -$284M. Management is explicit that it 'will require substantial additional funding' and 'may be unable to raise additional funds… when needed on acceptable terms, or at all.' Survival depends on the capital markets, not the business.